Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official title: A phase 3 randomized, double-blind, 52-week placebo-controlled, multi-center study investigating the efficacy, safety, and tolerability of ritlecitinib in adult and adolescent participants with non segmental vitiligo.
Brief Summary: A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Vitiligo (Active and Stable)
Detailed Description: Study B7981040 is a Phase 3 randomized, double-blind, 52-week placebo-controlled, multi center study investigating the efficacy, safety, and tolerability of ritlecitinib in adult and adolescent participants with non segmental vitiligo (both active and stable vitiligo).
Actual Study Start Date: December 1, 2022
Estimated Study Completion Date: June 19, 2025
Contact: Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
https://beta.clinicaltrials.gov/study/NCT05583526
FAQOther Questions
- What is the best therapy for localized vitiligo?
Localized vitiligo, where the white patches are limited to one or a few areas of the body, can be managed with a few treatment approaches. The best therapy usually depends on th...
- What tests should be done?
A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...
- What is vitiligo?
Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Cont...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.